Navigation Links
MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
Date:9/17/2008

DANBURY, Conn., Sept. 17 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has proposed to the United States Food and Drug Administration to use AFRESA as the trade name for its Technosphere Insulin System.

AFRESA (pronounced uh-FRESS-uh) was unveiled today by Alfred Mann, Chairman and Chief Executive Officer of MannKind, during a ceremony at the company's Danbury, Conn., location that marked the completion and dedication of a new facility for the commercial manufacture of the product.

The events in Danbury included a building dedication, a luncheon, and tours of the 263,900 sq. ft. production facility for invitees, who included investors, medical and industry professionals, scientists, employees, and government officials. The completion of the building phase of this project brings MannKind's investment in plant and equipment at the Danbury site to almost $200 million. The facility is now in the process of being qualified and readied for preapproval inspection by the FDA.

Featuring state-of-the-art equipment and processes and redundant utilities, the new facility includes expansion space that will allow production capacity to be increased to meet expected demand over the next few years. The architect for the project was Kling Stubbins. The engineering firm was Clark Richardson Biskup and the construction manager was Torcon.

MannKind is proud to note that its facility expansion received the 2008 Bronze Vision Award in the Corporate Owner: Industrial/Manufacturing category at the Ninth Annual Constructech Vision Award ceremony, held in Chicago on August 21, 2008. The Constructech Vision Awards honor construction and engineering projects that have solved critical business issues
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... says the company is making good progress in evaluating the full range of ... tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and repair ...
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that ... dairy operation and presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in ... dairy cows and increased milk fat content. Also, feed containing Stay Strong™ for Dairy ...
(Date:7/28/2015)... 2015 People with a common form of ... and sometimes profound improvements in their hearing and understanding ... a new multicenter study led by specialists at NYU ... online ahead of print in the journal The Laryngoscope July ... in the United States implanted ...
(Date:7/28/2015)... 21, 2015 Research ... addition of the "Analysis of the Global ... offering. Globally, flow cytometry remains a ... proliferation, cancer, and stem cells. But the market ... because of demand from underdeveloped nations to quantitate ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2
... Renovis, Inc.,(Nasdaq: RNVS ), today announced that Glass ... ISS/Risk Metrics in recommending that Renovis,stockholders vote "FOR" the ... the Special Stockholders Meeting scheduled for May,1, 2008. In ... will be,converted into the right to receive the equivalent ...
... measurement helps physicians guide therapy for ... cardiometabolic risk patients, ... apoB are now recognized as valid, accurate and recommended,methods of ... risk (CMR). The VAP(R) Cholesterol Test (Atherotech, Inc.),is the only ...
... Growth in Agriculture and Emerging ... Markets, WILMINGTON, Del., April 22 ... $1.01 in the prior year. Excluding a significant item charge in ... Sales grew 9 percent to $8.6 billion, reflecting 6 percent higher local ...
Cached Biology Technology:Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 2Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 3Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 2Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 3DuPont Reports First Quarter Earnings Growth of Over 20 Percent 2DuPont Reports First Quarter Earnings Growth of Over 20 Percent 3DuPont Reports First Quarter Earnings Growth of Over 20 Percent 4DuPont Reports First Quarter Earnings Growth of Over 20 Percent 5DuPont Reports First Quarter Earnings Growth of Over 20 Percent 6DuPont Reports First Quarter Earnings Growth of Over 20 Percent 7DuPont Reports First Quarter Earnings Growth of Over 20 Percent 8DuPont Reports First Quarter Earnings Growth of Over 20 Percent 9DuPont Reports First Quarter Earnings Growth of Over 20 Percent 10DuPont Reports First Quarter Earnings Growth of Over 20 Percent 11DuPont Reports First Quarter Earnings Growth of Over 20 Percent 12DuPont Reports First Quarter Earnings Growth of Over 20 Percent 13DuPont Reports First Quarter Earnings Growth of Over 20 Percent 14DuPont Reports First Quarter Earnings Growth of Over 20 Percent 15DuPont Reports First Quarter Earnings Growth of Over 20 Percent 16DuPont Reports First Quarter Earnings Growth of Over 20 Percent 17DuPont Reports First Quarter Earnings Growth of Over 20 Percent 18
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)... 8, 2015 The consumer products industry ... must have products such as wearables, smart wallets & other ... biometrics based devices continues to rapidly grow.  Biometrics & Wearable ... NXTD ), Google Inc. (NASDAQ: GOOG ), Apple Inc. ... GoPro, Inc. (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... Lung cancer is the most commonly diagnosed cancer in the ... but scientists are working on ways to improve their understanding ... gather in San Diego at the San Diego Marriott Marquis ... Conference on Molecular Origins of Lung Cancer: Biology, Therapy and ...
... - Newly published research by scientists at Oregon Health ... early embryonic stem cells develop and take part in ... place at OHSU,s Oregon National Primate Research Center, has ... monkeys -- monkeys developed from stem cells taken from ...
... UCLA researchers have identified how a component of an ... the plant Hovenia, counteracts acute alcohol intoxication and withdrawal ... the action of alcohol on the brain and neurons ... side effects, in an early study with rats. Specifically, ...
Cached Biology News:Lung cancer conference to focus on new diagnostic techniques, potential treatments 2OHSU research produces the world's first primate chimeric offspring 2
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
...
Biology Products: